Systematic Financial Management LP trimmed its position in shares of Celgene Co. (NASDAQ:CELG) by 7.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,105 shares of the biopharmaceutical company’s stock after selling 1,504 shares during the period. Systematic Financial Management LP’s holdings in Celgene were worth $2,932,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Iberiabank Corp increased its holdings in Celgene by 7.5% in the 2nd quarter. Iberiabank Corp now owns 10,901 shares of the biopharmaceutical company’s stock valued at $1,416,000 after purchasing an additional 764 shares in the last quarter. Heritage Investors Management Corp acquired a new stake in Celgene in the 2nd quarter valued at $2,383,000. Capital Investment Advisors LLC increased its holdings in Celgene by 16.6% in the 2nd quarter. Capital Investment Advisors LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 397 shares in the last quarter. New England Research & Management Inc. increased its holdings in Celgene by 12.4% in the 2nd quarter. New England Research & Management Inc. now owns 11,184 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 1,234 shares in the last quarter. Finally, Fulton Bank N.A. increased its holdings in Celgene by 4.0% in the 2nd quarter. Fulton Bank N.A. now owns 25,623 shares of the biopharmaceutical company’s stock valued at $3,328,000 after purchasing an additional 996 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Celgene Co. (CELG) opened at $102.02 on Thursday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a market cap of $80,320.00, a PE ratio of 24.06, a PEG ratio of 0.67 and a beta of 1.77.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the company posted $1.58 earnings per share. Celgene’s revenue was up 10.2% on a year-over-year basis. research analysts forecast that Celgene Co. will post 6.7 EPS for the current fiscal year.

Several analysts recently issued reports on CELG shares. BMO Capital Markets increased their price target on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a report on Wednesday. Oppenheimer reiterated a “buy” rating and issued a $170.00 price target on shares of Celgene in a report on Friday, October 20th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Finally, Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $130.95.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/celgene-co-celg-shares-sold-by-systematic-financial-management-lp/1812031.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.